Cargando…
Dupilumab improve acquired reactive perforating collagenosis characterized by type 2 inflammation
BACKGROUND: Acquired reactive perforating collagenosis (ARPC) is a clinically challenging disease with an unclear pathogenesis. OBJECTIVE: To evaluate the efficacy and safety of dupilumab for the treatment of ARPC, and analyze the expression of type 2 inflammation-related molecules in ARPC lesions....
Autores principales: | Liu, Ben, Wu, Yibei, Wu, Xiaoyan, Zhong, Xinyu, Xue, Ruzeng, Zhang, Zhenying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449391/ https://www.ncbi.nlm.nih.gov/pubmed/37638036 http://dx.doi.org/10.3389/fimmu.2023.1240262 |
Ejemplares similares
-
Reactive perforating collagenosis successfully treated with dupilumab
por: Gil‐Lianes, Javier, et al.
Publicado: (2022) -
Acquired reactive perforating collagenosis
por: Wang, Chen, et al.
Publicado: (2020) -
Dupilumab may be an alternative option in the treatment of acquired reactive perforating collagenosis combined with AD
por: Ying, Yang, et al.
Publicado: (2021) -
Allopurinol in the treatment of acquired reactive perforating collagenosis()
por: Tilz, Hemma, et al.
Publicado: (2013) -
Dermoscopic Patterns of Acquired Reactive Perforating Collagenosis
por: Elmas, Ömer Faruk, et al.
Publicado: (2020)